Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Japanese Patients with Relapsed/Refractory Multiple Myeloma from the Phase 1/2 Monumental-1 Study

Shigeki Ito, Yoshiaki Kuroda, Kazutaka Sunami, Kosei Matsue, Kazunori Imada, Hideto Tamura, Mikihiro Takamoto, Hiroshi Yamazaki, Ei Fujikawa, Lixia Pei, Tara J Masterson, Michela Campagna, Bonnie W Lau, Yasushi Takamatsu

Blood (2024) 144 (Supplement 1): 7011.

https://doi.org/10.1182/blood-2024-199663

Published: 2024

Journal Articles

Extracellular CD30 and ADAM10/17 Regulate Brentuximab Vedotin-Induced Cell Death in an Adult T-Cell Leukemia Cell Line

Keisuke Sato, Tomohiro Kozako, Akira Nakano, Kentaro Ogata, Hidetoshi Kamimura, Hidenori Sasaki, Yasushi Takamatsu, Shigeki Takemoto, Shin-Ichiro Honda

Blood (2023) 142 (Supplement 1): 5803.

https://doi.org/10.1182/blood-2023-173221

Published: 2023

Journal Articles

Interim PET-Guided ABVD or ABVD/Escalated BEACOPP for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma (JCOG1305, INNOVATE-HL study)

Blood (2022) 140 (Supplement 1): 3718–3720.

https://doi.org/10.1182/blood-2022-157006

Published: 2022

Journal Articles

Progression of Disease within 5 Months of Adult T-Cell Leukemia-Lymphoma (ATL5) As a Clinical Endpoint for High-Risk Mortality Outcomes in the Real-World Setting: A Multinational Cohort Analysis

Bryan Valcarcel, Haruhiko Sano, Hiroo Katsuya, Atae Utsunomiya, Maki Otsuka, Masaharu Miyahara, Yasushi Takamatsu, Kenji Ishitsuka, Shinya Kimura, Junji Suzumiya, Kazuo Tamura, Daniel J Enriquez, Denisse Castro, Brady E Beltran, Henry Idrobo, Camila Peña, Lorena Fiad, Juan Carlos Ramos, Luis Enrique Malpica Castillo

Blood (2022) 140 (Supplement 1): 6664–6665.

https://doi.org/10.1182/blood-2022-168101

Published: 2022

Journal Articles

Clinical Features, Treatment Patterns, and Outcomes Among 837 Patients with Adult T-Cell Leukemia-Lymphoma in the Real-World Setting: A Comparison of Endemic Regions

Blood (2022) 140 (Supplement 1): 1072–1073.

https://doi.org/10.1182/blood-2022-168334

Published: 2022

Journal Articles

Minimal Residual Disease (MRD) Status after Induction Therapy Is a Strong Prognostic Factor in the Treatment of Adult Ph (-) Acute Lymphoblastic Leukemia (ALL): Results of a Prospective Study (ALL MRD2008 Study)

Koji Nagafuji, MD PhD, Toshihiro Miyamoto, MD PhD, Tetsuya Eto, MD PhD, Ryosuke Ogawa, MD PhD, Naoyuki Uchida, MD PhD, Ken Takase, MD, Noriaki Kawano, MD PhD, Tomoaki Fujisaki, MD PhD, Tomohiko Kamimura, MD PhD, Atsushi Wake, MD PhD, Hirokazu Okumura, MD PhD, Yasuhiko Miyazaki, MD PhD, Yasushi Takamatsu, MD PhD, Toshiro Kurokawa, MD PhD, Yuju Ohno, MD PhD, Shouhei Yokota, MP.Path, Koichi Akashi, MD PhD

Blood (2018) 132 (Supplement 1): 3970.

https://doi.org/10.1182/blood-2018-99-112848

Published: 2018

Journal Articles

Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab (RW-CHOP) for Previously Untreated DLBCL: JCOG0601

Blood (2018) 132 (Supplement 1): 4194.

https://doi.org/10.1182/blood-2018-99-110201

Published: 2018

Journal Articles

Classical Empiric Antifungal Therapy Vs. D-Index Guided Early Therapy Using Micafungin for Persistent Febrile Neutropenia (CEDMIC trial): A Randomized Controlled Trial from Japan FN Study Group

Shun-Ichi Kimura, MD PhD, Yoshinobu Kanda, MD PhD, Masaki Iino, MD PhD, Takahiro Fukuda, MD PhD, Emiko Sakaida, MD PhD, Tatsuo Oyake, Hiroki Yamaguchi, MD PhD, Shin-ichiro Fujiwara, MD PhD, Junji Suzumiya, MD PhD, Akinao Okamoto, MD PhD, Hiroyuki Fujita, MD PhD, Yasushi Takamatsu, MD PhD, Yoshio Saburi, MD PhD, Jun Yamanouchi, MD PhD, Itaru Matsumura, MD, Souichi Shiratori, Moritaka Gotoh, MD PhD, Shingen Nakamura, MD PhD, Kazuo Tamura, MD PhD

Blood (2018) 132 (Supplement 1): 816.

https://doi.org/10.1182/blood-2018-99-111154

Published: 2018

Journal Articles

Randomized Phase II Study of R-CHOP-14 Versus R-CHOP-14 Followed By Chaser As Induction Therapy for High-Dose Chemotherapy (HDT), LEED, and Autologous Stem-Cell Transplantation (ASCT) in Poor-Risk Diffuse Large B-Cell Lymphoma (DLBCL): Japan Clinical Oncology Group (JCOG) Study (JCOG0908)

Blood (2017) 130 (Supplement 1): 4127.

https://doi.org/10.1182/blood.V130.Suppl_1.4127.4127

Published: 2017

Journal Articles

Oral HDAC Inhibitor HBI8000 in Japanese Patients with Non-Hodgkin Lymphoma (NHL): Phase I Safety and Efficacy Results

Makoto Onizuka, MD PhD, Kiyoshi Ando, MD PhD, Makoto Yoshimitsu, MD, PhD, Takashi Ishida, MD PhD, S Yoshida, MD, Ilseung Choi, MD, Michihiro Hidaka, MD, Yasushi Takamatsu, MD PhD, Midori Nagashima, Akira Miyazato, MD PhD, Joachim P Schupp, MD, Alain Rolland, PharmD, PhD, Mireille Gillings, PhD, Gloria T. Lee, MD PhD, Kensei Tobinai, MD PhD

Blood (2016) 128 (22): 1827.

https://doi.org/10.1182/blood.V128.22.1827.1827

Published: 2016

Journal Articles

Safety, Efficacy, and Pharmacokinetic Profiles of Intravenous Rigosertib in Japanese Patients with Recurrent/Relapsed or Refractory Myelodysplastic Syndromes: A Multicenter, Open-Label Phase I Clinical Study

Michinori Ogura, Yukio Kobayashi, MD PhD, Shiro Kubonishi, MD PhD, Michihiro Hidaka, MD PhD, Toshiki Uchida, MD PhD, Yasushi Takamatsu, MD PhD

Blood (2016) 128 (22): 5549.

https://doi.org/10.1182/blood.V128.22.5549.5549

Published: 2016

Journal Articles

Predictive Significance of Serum Beta 2-Microglobulin Levels and M-Protein Velocity for Symptomatic Progression of Smoldering Multiple Myeloma

Tsuyoshi Muta, MDPhD, Shinsuke Iida, MD PhD, Kosei Matsue, MD PhD, Kazutaka Sunami, Jun Isoda, MD PhD, Naoko Harada, MD PhD, Yoshio Saburi, MD PhD, Seiichi Okamura, MD PhD, Kyouya Kumagae, MD PhD, Junichi Watanabe, MD PhD, Junya Kuroda, MD PhD, Kenichi Aoki, MD, Ryosuke Ogawa, MD PhD, Toshihiro Miyamoto, MD PhD, Koichi Akashi, MD PhD, Yasushi Takamatsu, MD PhD

Blood (2014) 124 (21): 3379.

https://doi.org/10.1182/blood.V124.21.3379.3379

Published: 2014

Journal Articles

Prognostic Significance Of S-Phase Kinase-Associated Protein 2 (Skp2) In DLBCL Patients Treated With Upfront Autologous Peripheral Blood Stem Cell Transplantation

Blood (2013) 122 (21): 3022.

https://doi.org/10.1182/blood.V122.21.3022.3022

Published: 2013

Journal Articles

Once-Weekly Subcutaneous Bortezomib Plus Oral Cyclophosphamide and Dexamethasone Therapy For Relapsed Or Refractory Multiple Myeloma

Yasushi Takamatsu, MD, PhD, Yutaka Imamura, MD, Tomonori Nakazato, MD, Naokuni Uike, MD, PhD, Kaname Miyashita, MD, Yoshio Saburi, MD, PhD, Naoki Harada, MD, Shuichi Ota, MD, PhD, Rie Imamura, MD, Toshihiro Miyamoto, MD

Blood (2013) 122 (21): 5382.

https://doi.org/10.1182/blood.V122.21.5382.5382

Published: 2013

Journal Articles

Minimal Residual Disease Negative Status At the End of Induction Therapy Is a Potent Prognostic Marker in Adult Non-Ph Acute Lymphoblastic Leukemia: Results of the ALL MRD2002 Study

Koji Nagafuji, MD, PhD, Toshihiro Miyamoto, MD, PhD, Tetsuya Eto, MD, PhD, Tomohiko Kamimura, MD, Shuichi Taniguchi, MD, PhD, Takashi Okamura, MD, PhD, Eiichi Ohtsuka, MD, PhD, Takashi Yoshida, MD, Masakazu Higuchi, MD, PhD, Goichi Yoshimoto, MD, PhD, Tomoaki Fujisaki, MD, PhD, Yasunobu Abe, MD, PhD, Yasushi Takamatsu, MD, PhD, Shouhei Yokota, MD, PhD, Koichi Akashi, MD, PhD., Mine Harada, MD, PhD

Blood (2011) 118 (21): 2581.

https://doi.org/10.1182/blood.V118.21.2581.2581

Published: 2011

Journal Articles

A Phase I/II Study of Bortezomib in Combination with Doxorubicin and Intermediate-Dose Dexamethasone (iPAD therapy) for Relapsed or Refractory Multiple Myeloma

Yasushi Takamatsu, MD, PhD, Kazutaka Sunami, MD, PhD, Tsuyoshi Muta, MD, PhD, Junichi Tsukada, MD, PhD, Toshihiro Miyamoto, MD, PhD, Tetsuya Eto, MD, PhD, Masakazu Higuchi, MD, PhD, Hiroyuki Hata, MD, PhD, Junji Suzumiya, MD, PhD, Kazuo Tamura, MD, PhD

Blood (2011) 118 (21): 5137.

https://doi.org/10.1182/blood.V118.21.5137.5137

Published: 2011

Journal Articles

Heterozygous ITGA2B R995W mutation inducing constitutive activation of the αIIbβ3 receptor affects proplatelet formation and causes congenital macrothrombocytopenia

Shinji Kunishima, Hirokazu Kashiwagi, Makoto Otsu, Naoya Takayama, Koji Eto, Masafumi Onodera, Yuji Miyajima, Yasushi Takamatsu, Junji Suzumiya, Kousaku Matsubara, Yoshiaki Tomiyama, Hidehiko Saito

Blood (2011) 117 (20): 5479–5484.

https://doi.org/10.1182/blood-2010-12-323691

Published: 2011

Includes: Supplemental data

Journal Articles

Hepatic toxicity and prognosis in hepatitis C virus–infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis

Blood (2010) 116 (24): 5119–5125.

https://doi.org/10.1182/blood-2010-06-289231

Published: 2010

Includes: Supplemental data

Journal Articles

Mechanisms of Discrepancy Between CD33 Expression and Gemtuzumab Ozogamicin-Induced Cytotoxicity in Leukemia Cells.

Yasushi Takamatsu, MD, Shiro Jimi, PhD, Nanako Toyota, Shuuji Hara, PhD, Yuka Yoshimura, Junji Suzumiya, MD, Kazuo Tamura, MD

Blood (2009) 114 (22): 4812.

https://doi.org/10.1182/blood.V114.22.4812.4812

Published: 2009

Journal Articles

The Impact of Outcome and Hepatic Toxicity in HCV-Infected Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab Plus CHOP Therapy; A Retrospective Multicenter Japanese Analysis.

Blood (2009) 114 (22): 2700.

https://doi.org/10.1182/blood.V114.22.2700.2700

Published: 2009

NARROW

Efficacy and Safety of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Japanese Patients with Relapsed/Refractory Multiple Myeloma from the Phase 1/2 Monumental-1 Study

Extracellular CD30 and ADAM10/17 Regulate Brentuximab Vedotin-Induced Cell Death in an Adult T-Cell Leukemia Cell Line

Interim PET-Guided ABVD or ABVD/Escalated BEACOPP for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma (JCOG1305, INNOVATE-HL study)

Progression of Disease within 5 Months of Adult T-Cell Leukemia-Lymphoma (ATL5) As a Clinical Endpoint for High-Risk Mortality Outcomes in the Real-World Setting: A Multinational Cohort Analysis

Clinical Features, Treatment Patterns, and Outcomes Among 837 Patients with Adult T-Cell Leukemia-Lymphoma in the Real-World Setting: A Comparison of Endemic Regions

Minimal Residual Disease (MRD) Status after Induction Therapy Is a Strong Prognostic Factor in the Treatment of Adult Ph (-) Acute Lymphoblastic Leukemia (ALL): Results of a Prospective Study (ALL MRD2008 Study)

Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab (RW-CHOP) for Previously Untreated DLBCL: JCOG0601

Classical Empiric Antifungal Therapy Vs. D-Index Guided Early Therapy Using Micafungin for Persistent Febrile Neutropenia (CEDMIC trial): A Randomized Controlled Trial from Japan FN Study Group

Randomized Phase II Study of R-CHOP-14 Versus R-CHOP-14 Followed By Chaser As Induction Therapy for High-Dose Chemotherapy (HDT), LEED, and Autologous Stem-Cell Transplantation (ASCT) in Poor-Risk Diffuse Large B-Cell Lymphoma (DLBCL): Japan Clinical Oncology Group (JCOG) Study (JCOG0908)

Oral HDAC Inhibitor HBI8000 in Japanese Patients with Non-Hodgkin Lymphoma (NHL): Phase I Safety and Efficacy Results

Safety, Efficacy, and Pharmacokinetic Profiles of Intravenous Rigosertib in Japanese Patients with Recurrent/Relapsed or Refractory Myelodysplastic Syndromes: A Multicenter, Open-Label Phase I Clinical Study

Predictive Significance of Serum Beta 2-Microglobulin Levels and M-Protein Velocity for Symptomatic Progression of Smoldering Multiple Myeloma

Prognostic Significance Of S-Phase Kinase-Associated Protein 2 (Skp2) In DLBCL Patients Treated With Upfront Autologous Peripheral Blood Stem Cell Transplantation

Once-Weekly Subcutaneous Bortezomib Plus Oral Cyclophosphamide and Dexamethasone Therapy For Relapsed Or Refractory Multiple Myeloma

Minimal Residual Disease Negative Status At the End of Induction Therapy Is a Potent Prognostic Marker in Adult Non-Ph Acute Lymphoblastic Leukemia: Results of the ALL MRD2002 Study

A Phase I/II Study of Bortezomib in Combination with Doxorubicin and Intermediate-Dose Dexamethasone (iPAD therapy) for Relapsed or Refractory Multiple Myeloma

Heterozygous ITGA2B R995W mutation inducing constitutive activation of the αIIbβ3 receptor affects proplatelet formation and causes congenital macrothrombocytopenia

Hepatic toxicity and prognosis in hepatitis C virus–infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis

Mechanisms of Discrepancy Between CD33 Expression and Gemtuzumab Ozogamicin-Induced Cytotoxicity in Leukemia Cells.

The Impact of Outcome and Hepatic Toxicity in HCV-Infected Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab Plus CHOP Therapy; A Retrospective Multicenter Japanese Analysis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only